Immix Biopharma shares surge 30.04% premarket after NXC-201 Phase 2 trial shows 75% complete response rate in AL amyloidosis.

Immix Biopharma surged 30.04% in premarket trading following the release of robust Phase 2 clinical trial results for its CAR-T therapy NXC-201 in relapsed/refractory AL Amyloidosis. The therapy demonstrated a 75% complete response rate (15/20 patients) and MRD negativity in four of five pending cases, suggesting a potential future 95% CR rate. These results, presented at ASH 2025, highlight NXC-201’s potential to address a high-unmet-need market, with a planned 2026 Biologics License Application. Additionally, the company announced a $100 million equity offering to fund NXC-201 development, further signaling confidence in the program’s regulatory and commercial trajectory. The data’s strength and the BLA timeline likely drove immediate investor optimism.